Phase 2 N=32 Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Opioid Abuse
Primary: Subjective Ratings of "Good" Drug Effect — 37; 35; 35 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=105 A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
Colitis, Ulcerative
Primary: Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8 — 3.13; 3.10; 0.10; -0.30 scores on a scale — p=0.96
Phase 2 N=95 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
Phase 2 N=6 The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
Pulmonary Hypertension · Pulmonary Arterial Hypertension
Primary: Pain Score on a Visual Analogue Scale — 2.89 Visual Analogue Scale — p=0.03
Phase 2 N=25 High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
Head and Neck Cancer
Primary: Survival Rate of Patients — 33 months
Phase 2 N=34 Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Multiple Myeloma
Primary: Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response — 8; 7 participants — p=1.0000
Phase 2 N=100 ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Actinic Keratosis
Primary: Treatment Success at End of Study Visit — 66.7; 65.2; 76.0; 66.7 percentage of participants — p=0.799
Phase 2 N=1,075 Green Tea and Reduction of Breast Cancer Risk
Breast Cancer
Primary: Mammographic Density — 22.71; 21.84; 22.09; 21.13 Percent
Phase 2 N=36 A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
Gastric Cancer
Primary: Percentage of Participants Who Are Progression-Free at 12 Weeks (Progression-Free Survival [PFS] Rate at 12 Weeks) — 23.8 Percentage of Participants
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
Phase 2 N=22 A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive · Lung Diseases · Respiratory Tract Diseases
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) — 1.61; 1.58; 1.62; 1.62 Liter
Phase 2 N=66 A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score at Week 3 — 36.778; 38.273; 36.135…
Phase 2 N=135 A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 38.4; 24.1 weeks
Phase 2 N=11 Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
PANCREAS · Neuroendocrine
Primary: Overall Response. — 6; 2 participants
Phase 2 N=66 Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Multiple Myeloma
Primary: Objective Response (OR) Rate — 0.41 proportion of participants